Eagle Asset Management Inc. Takes Position in AxoGen, Inc. (NASDAQ:AXGN)

Eagle Asset Management Inc. purchased a new position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 123,279 shares of the medical equipment provider's stock, valued at approximately $1,728,000. Eagle Asset Management Inc. owned about 0.28% of AxoGen at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Quest Partners LLC boosted its holdings in shares of AxoGen by 23,066.7% in the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 2,076 shares during the period. nVerses Capital LLC bought a new stake in AxoGen during the 3rd quarter valued at $56,000. Koss Olinger Consulting LLC purchased a new stake in shares of AxoGen in the 2nd quarter worth $75,000. Lazard Asset Management LLC grew its position in shares of AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider's stock worth $93,000 after buying an additional 2,671 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of AxoGen during the second quarter valued at $125,000. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Stock Up 1.0 %

Shares of NASDAQ AXGN traded up $0.14 during mid-day trading on Tuesday, reaching $13.61. 216,353 shares of the company were exchanged, compared to its average volume of 400,715. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $15.90. The firm has a 50-day moving average of $13.73 and a 200 day moving average of $10.68. The stock has a market cap of $598.95 million, a price-to-earnings ratio of -42.72 and a beta of 1.13. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67.

Analyst Ratings Changes

A number of research firms recently weighed in on AXGN. StockNews.com raised shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. JMP Securities boosted their price target on shares of AxoGen from $17.00 to $20.00 and gave the company a "market outperform" rating in a report on Friday, August 9th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, AxoGen has a consensus rating of "Buy" and a consensus price target of $15.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.